SCA
BMRN icon

Strategic Capital Alternatives’s BioMarin Pharmaceuticals BMRN Stock Holding History

Strategic Capital Alternatives’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-214
Closed -$29K – 323
2015
Q2 		$29K Buy
+214
New +$26.5K 0.01% 345
2014
Q4 		– Sell
-214
Closed -$15K – 130
2014
Q3 		$15K Buy
+214
New +$14.1K 0.01% 348

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Strategic Capital Alternatives's BMRN Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 214 shares — an estimated $29K sold.

Strategic Capital Alternatives first reported a position in BMRN in Q3 2014 and held it in 2 quarters. The position peaked at $29K in Q2 2015. 394 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 214 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $29K.
  • Strategic Capital Alternatives first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Strategic Capital Alternatives's BioMarin Pharmaceuticals position peaked at $29K in Q2 2015.
  • 394 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.